Adipotide, Purity 99%, white powder, direct sales from Chinese factory

HKPao

D-Lysine, L-cysteinyl-L-lysylglycylglycyl-L-arginyl-L-alanyl-L-lysyl-L-α-aspartyl-L-cysteinylglycylglycyl-D-lysyl-D-leucyl-D-alanyl-D-lysyl-D-leucyl-D-alanyl-D-lysyl-D-lysyl-D-leucyl-D-alanyl-D-lysyl-D-leucyl-D-alanyl-;Adipotide Powder;Weight Loss Peptides Adipotide Adipotide Ftpp;HKPao;Adipotide (FTPP) 5mg 10mg;Prohibitin-targeting peptide 1

859216-15-2

C111H206N36O28S2

GZESIPHLGJDZRG-XRIURATCNA-N

2557.21

200-001-8

Polypeptide

1.40±0.1 g/cm3(Predicted)

Chimeric peptidomimetic (fat-targeting vascular disruptor)

Research compound — Not FDA approved, clinical development discontinued

A synthetic chimeric peptide composed of a fat-vascular-targeting cyclic peptide (CKGGRAKDC) linked via a GG spacer to a pro-apoptotic peptide (KLAKLAK)2. Adipotide selectively binds prohibitin in the vasculature of white adipose tissue, then delivers the pro-apoptotic domain to induce vascular disruption, causing fat tissue death. In primate studies (2011), it produced significant weight loss (~11%) but also caused renal toxicity, leading to development discontinuation.

Adipotide is not a receptor agonist. It functions as a targeted vascular disruptor. Functional activity is measured by tissue-specific apoptosis, not traditional EC50.

PubChem: Adipotide (CID 163360068); Kolonin MG, et al. Sci Transl Med. 2004;6(148):148ra16.DOI

PubChem

Sci Transl Med: Kolonin MG, et al. (2004) — Adipotide mechanism; ChemicalBook: Adipotide (CAS 859216-15-2)

Adipotide is NOT FDA-approved or EMA-approved. It is a research compound only. Clinical development was discontinued due to renal toxicity observed in primate studies. This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.